Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSK | P43235 | 10/20 | 0.76 |
| ▸ | CTSL | P07711 | 4/20 | 0.70 |
| ▸ | CTSB | P07858 | 4/20 | 0.70 |
| ▸ | CTSS | P25774 | 3/20 | 0.70 |
| ▸ | CAPN1 | P07384 | 2/20 | 0.64 |
| ▸ | CAPN2 | P17655 | 1/20 | 0.64 |
| ▸ | MME | P08473 | 1/20 | 0.62 |
| ▸ | ECE1 | P42892 | 1/20 | 0.62 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2366985 | 1.00 | CTSK (0.76) | CTSKCTSLCTSBCTSSCAPN1 | |
| SCHEMBL222158 | 1.00 | CTSK (0.76) | CTSKCTSLCTSBCTSSCAPN1 | |
| SCHEMBL8583018 | 0.95 | CTSK (0.69) | CTSKCTSLCTSBCTSSCAPN1 | |
| SCHEMBL20770085 | 0.95 | CTSK (0.77) | CTSKCTSLCTSBCTSSCAPN1 | |
| SCHEMBL14148467 | 0.95 | CTSK (0.77) | CTSKCTSLCTSBCTSSCAPN1 | |
| SCHEMBL25406813 | 0.95 | CTSK (0.77) | CTSKCTSLCTSBCTSSCAPN1 | |
| SCHEMBL4872585 | 0.95 | CTSK (0.77) | CTSKCTSLCTSBCTSSCAPN1 | |
| SCHEMBL7318823 | 0.95 | CTSK (0.69) | CTSKCTSLCTSBCTSSCAPN1 | |
| SCHEMBL8823918 | 0.95 | CTSK (0.77) | CTSKCTSLCTSBCTSSCAPN1 | |
| SCHEMBL2930262 | 0.95 | CTSK (0.77) | CTSKCTSLCTSBCTSSCAPN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 296 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118000312-B | Application of N-carbobenzoxy-leucine in reducing rumen methane emission of ruminants | 南京农业大学 | 2025-05-13 | — | — | CN | claimed |
| CN-118178252-A | Application of sea cucumber tetrapeptide and its derivatives in cosmetics | 上海湃肽生物科技有限公司 | 2024-06-14 | — | — | CN | claimed |
| CN-118000312-A | Application of N-carbobenzoxy-leucine in reducing rumen methane emission of ruminants | 南京农业大学 | 2024-05-10 | — | — | CN | claimed |
| CN-113861231-B | Amino acid modification-based bionic rubber and application thereof in preparation of aircraft tire tread rubber | 中国科学院长春应用化学研究所 | 2022-11-01 | — | — | CN | claimed |
| CN-114031702-A | Polypeptide modified butadiene-isoprene copolymer rubber, preparation method thereof and vulcanized rubber | 中国科学院长春应用化学研究所 | 2022-02-11 | — | — | CN | claimed |
| CN-113980162-A | Polypeptide modified polybutadiene rubber, preparation method thereof and vulcanized rubber | 中国科学院长春应用化学研究所 | 2022-01-28 | — | — | CN | claimed |
| CN-113861231-A | Amino acid modification-based bionic rubber and application thereof in preparation of aircraft tire tread rubber | 中国科学院长春应用化学研究所 | 2021-12-31 | — | — | CN | claimed |
| CN-113292454-A | AIE molecule with cinnamonitrile as framework structure and preparation method and application thereof | 宝鸡文理学院 | 2021-08-24 | — | — | CN | claimed |
| EP-0817795-B1 | NOVEL 4-SUBSTITUTED-3-PEPTIDYL-AZETIDIN-2-ONE DERIVATIVES USEFUL AS CYSTEINE PROTEINASE INHIBITOR | NAEJA PHARMACEUTICAL INC (CA) | 2000-11-15 | — | — | EP | claimed |
| US-5986108-A | ENZYME INHIBITORS | SYNPHAR LABORATORIES, INC. (CA) | 1999-11-16 | — | — | US | claimed |
| EP-0817795-A1 | NOVEL 4-SUBSTITUTED-3-PEPTIDYL-AZETIDIN-2-ONE DERIVATIVES USEFUL AS CYSTEINE PROTEINASE INHIBITOR | SYNPHAR LABORATORIES INC. (CA) | 1998-01-14 | — | — | EP | claimed |
| WO-1996032408-A1 | NOVEL 4-SUBSTITUTED-3-PEPTIDYL-AZETIDIN-2-ONE DERIVATIVES USEFUL AS CYSTEINE PROTEINASE INHIBITOR | SYNPHAR LABORATORIES, INC. (US) | 1996-10-17 | — | — | WO | claimed |
| EP-0040435-B1 | PEPTIDE DERIVATIVES AND PROCESS FOR THE PREPARATION THEREOF | Eisai Co., Ltd. (JP) | 1983-07-20 | — | — | EP | claimed |
| US-20260116857-A1 | INHIBITORS OF CYSTEINE PROTEASES AND METHODS OF USE THEREOFS | PARDES BIOSCIENCES INC (US) | 2026-04-30 | — | — | US | disclosed |
| US-20260034084-A1 | MODULATORS OF SESTRIN-GATOR2 INTERACTION AND USES THEREOF | NAVITOR PHARM INC (US) | 2026-02-05 | — | — | US | disclosed |
| US-12427130-B2 | Modulators of Sestrin-GATOR2 interaction and uses thereof | NAVITOR PHARMACEUTICALS, INC. (US) | 2025-09-30 | — | — | US | disclosed |
| EP-0094815-A2 | Oligopeptide prodrugs | SMITHKLINE BECKMAN CORPORATION (US) | 1983-11-23 | — | — | EP | disclosed |
| US-4382142-A | ANTITUMOR AND ANTICARCINOGENIC AGENTS; LEUKEMIA | KOWA CO., LTD. (JP) | 1983-05-03 | — | — | US | disclosed |
| EP-0077274-A1 | 3-Amino-2-hydroxy-4-phenylbutanoic acid derivatives and pharmaceutical composition containing the same | ZAIDAN HOJIN BISEIBUTSU KAGAKU KENKYU KAI (JP) | 1983-04-20 | — | — | EP | disclosed |
| US-4338309-A | AMINOGLYCOSIDE ANTIBIOTICS | ABBOTT LABORATORIES (US) | 1982-07-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260034084-A1 | MODULATORS OF SESTRIN-GATOR2 INTERACTION AND USES THEREOF | RICTOR, RPTOR, MTOR | CTSK 4241/4885CTSL 4055/4885CTSB 3871/4885 |
| US-20260116857-A1 | INHIBITORS OF CYSTEINE PROTEASES AND METHODS OF USE THEREOFS | CTRC, CTRL, CTSL | CTSK 50/4885CTSL 3/4885CTSB 14/4885 |
| US-12427130-B2 | Modulators of Sestrin-GATOR2 interaction and uses thereof | GATD3, GABRR2, GABRR3 | CTSK 4783/4885CTSL 4880/4885CTSB 4827/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.